On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 1:00:59 Webinar: Advancing DYNE-251 – An Investigational Medicine for Duchenne to Deliver for Patients 3 months ago Research & Clinical Trial Webinars,Webinars dyne therapeutics,DYNE-251 1:05:32 Webinar: Edgewise Therapeutics – Clinical Trials in Becker Muscular Dystrophy 3 months ago Research & Clinical Trial Webinars,Webinars edgewise 58:10 Webinar: Community Progress in Duchenne Newborn Screening 6 months ago Webinars feature,newborn screening 1:01:30 Webinar: Community Update with ITF Therapeutics – Introducing DUVYZAT™ (givinostat) 8 months ago Research & Clinical Trial Webinars,Webinars duvyzat,feature,givinostat,itf therapeutics 45:03 Webinar: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051 8 months ago Research & Clinical Trial Webinars,Webinars sarepta 39:33 Webinar: NS Pharma – Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 8 months ago Research & Clinical Trial Webinars,Webinars ns pharma 52:15 Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences 9 months ago Research & Clinical Trial Webinars,Webinars wave life sciences,WVE-N531 29:09 PTC Therapeutics — EMFLAZA® Landscape in 2024 9 months ago Care Webinars,Webinars emflaza,ptc therapeutics «1234…25»Page 2 of 25
by: Parent Project Muscular Dystrophy
